Investigation of anti-tumoral effect and safety of combination therapy LD-GP (low dose gemcitabine and paclitaxel) therapy and sorafenib in patients with cisplatin-resistant advanced urothelial cancer.

Investigation of anti-tumoral effect and safety of combination therapy LD-GP (low dose gemcitabine and paclitaxel) therapy and sorafenib in patients with cisplatin-resistant advanced urothelial cancer. - Efficacy and safety of combination therapy of low dose gemcitabine and paclitaxeltherapy with sorafenib in patients with cisplatin-resistant urothelial cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010957

Enrollment

Registered

2013-06-16

Start date

2013-03-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cisplatin-resistant urothelial cancer

Interventions

Gemcitabine (700 mg/m2): Day 1. Paclitaxel (70 mg/m2): Day 1. Sorafenib (400mg/day) Day 8 - 21. repeated every 28 days as long as possible.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CDDP-resistance. Advanced disease.

Exclusion criteria

Exclusion criteria: Blood examinations WBC: under 3,000 / mm3. Neut: under 1,500 / mm3. Plt: under 100,000/ mm3. Hgb: under 8 g/dl. T-Bil: over 1.5 mg/dl. s-Cr: over 2.0 mg/dl.

Design outcomes

Primary

Measure	Time frame
Frequency of adverse events. Overall survival. Quality of life.	—

Countries

Japan

Contacts

Public ContactYasuyoshi Miyata

Nagasaki University Hospital Urology

int.doc.miya@m3.dion.ne.jp095-819-7340

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026